EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Protective Effects of PACAP in Diabetic Complications: Retinopathy, Nephropathy and Neuropathy

Dora Reglodi, Andrea Tamas, Inez Bosnyak, Tamas Atlasz iD, Edina Szabo, Lina Li, Gabriella Horvath, Balazs Opper, Peter Kiss, Liliana Lucas, Grazia Maugeri iD, Agata Grazia D'Amico und 4 weitere

International Journal of Molecular Sciences · 03.10.2025 · 26 (19) · 9650

DOI: 10.3390/ijms26199650 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 03.10.2025. Verfasst von Dora Reglodi und 15 weiteren Autor:innen. Beteiligte Einrichtung: HUN REN-PTE PACAP Research Group, Department of Anatomy, University of Pecs Medical School, 7624 Pecs, Hungary. Hauptthemen laut MEDLINE: Pituitary Adenylate Cyclase-Activating Polypeptide, Diabetic Retinopathy, Diabetic Nephropathies, Diabetic Neuropathies. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 235 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NFKHI, National Brain Research Council, HUN-REN.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Pituitary adenylate cyclase-activating polypeptide (PACAP) is a neuropeptide exerting, among others, strong trophic and protective effects. It plays a role in several physiological functions, including glucose homeostasis. The protective effects of PACAP are mainly mediated via its specific PAC1 receptor by stimulating anti-inflammatory, anti-apoptotic and antioxidant pathways. The aim of the present review is to summarize data on the protective effects of PACAP in the three major complications of diabetes, retinopathy, nephropathy and neuropathy, as well as some other complications. In type 1 and type 2 diabetic retinopathy models and in glucose-exposed cells of the eye, PACAP counteracted the degeneration of retinal layers and inhibited apoptosis and factors leading to abnormal vessel growth. In models of nephropathy, kidney morphology was better retained after PACAP administration, with decreased apoptosis and fibrosis. In diabetic neuropathy, PACAP protected against axonal–myelin lesions and less activation in pain processing centers. This neuropeptide has several other beneficial effects in diabetes-induced complications like altered vascular response, cognitive deficits and atherosclerosis. The promising therapeutic effects of PACAP in several pathological conditions have encouraged researchers to design PACAP-related drugs and to develop ways to enhance tissue delivery. These intentions are expected to result in overcoming the hurdles preventing PACAP from being introduced into therapeutic treatments, including diabetes-related conditions.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pituitary Adenylate Cyclase-Activating PolypeptideDiabetic RetinopathyDiabetic NephropathiesDiabetic NeuropathiesDiabetes ComplicationsHumansAnimals

Stichwörter der Autor:innen

diabetic keratopathydiabetic nephropathydiabetic neuropathydiabetic retinopathy

Substanzen

Pituitary Adenylate Cyclase-Activating Polypeptide

Autor:innen und Institutionen

  • HUN REN-PTE PACAP Research Group, Department of Anatomy, University of Pecs Medical School, 7624 Pecs, Hungary.
  • Department of Sports Biology and Kinesiology, Faculty of Sciences, University of Pecs, 7624 Pecs, Hungary.
  • Section of Anatomy, Histology and Movement Sciences, Department of Biomedical and Biotechnological Sciences, University of Catania, 95123 Catania, Italy.
  • Department of Drug Sciences, University of Catania, 95123 Catania, Italy.

ORCID-Profile: Tamas Atlasz, Grazia Maugeri, Velia D'Agata

Förderung

  • NFKHI
  • National Brain Research Council
  • HUN-REN
  • NTA
  • TKP
  • National Research, Development and Innovation Fund
  • National Brain Research Program NAP3
  • sponsorship of the Hungarian Ministry of Culture and Innovation

Zitieren

APA

Reglodi, D., Tamas, A., Bosnyak, I., Atlasz, T., Szabo, E., Li, L., Horvath, G., Opper, B., Kiss, P., Lucas, L., Maugeri, G., D'Amico, A. G., D'Agata, V., Fabian, E., Reman, G., & Vaczy, A. (2025). Protective Effects of PACAP in Diabetic Complications: Retinopathy, Nephropathy and Neuropathy. International Journal of Molecular Sciences, 26(19), 9650. https://doi.org/10.3390/ijms26199650

Vancouver

Reglodi D, Tamas A, Bosnyak I, Atlasz T, Szabo E, Li L, et al. Protective Effects of PACAP in Diabetic Complications: Retinopathy, Nephropathy and Neuropathy. International Journal of Molecular Sciences. 2025;26(19):9650. doi:10.3390/ijms26199650

BibTeX
@article{Reglodi2025,
  author = {Reglodi, Dora and Tamas, Andrea and Bosnyak, Inez and Atlasz, Tamas and Szabo, Edina and Li, Lina and Horvath, Gabriella and Opper, Balazs and Kiss, Peter and Lucas, Liliana and Maugeri, Grazia and D'Amico, Agata Grazia and D'Agata, Velia and Fabian, Eszter and Reman, Gyongyver and Vaczy, Alexandra},
  title = {Protective Effects of PACAP in Diabetic Complications: Retinopathy, Nephropathy and Neuropathy},
  journal = {International Journal of Molecular Sciences},
  year = {2025},
  volume = {26},
  number = {19},
  pages = {9650},
  doi = {10.3390/ijms26199650}
}
Kostenlos starten →